pixlbio (formerly DefiniGEN)
Cambridge
About pixlbio (formerly DefiniGEN)
DefiniGEN was founded in April 2012 to industrialize the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. The company has world-leading expertise in the area of iPSC production and metabolic disease modelling. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective treatments. In addition the technology platform utilises fully defined and humanized conditions required for the development of regenerative medicine cellular therapies. DefiniGEN builds on intellectual property and knowledge resident at the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital and in addition has in-licensed the Yamanka induced pluripotent stem cell IP portfolio from iPS Academia Japan Inc.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $18.7M
- Funding stage: M&A
- Last round: Undisclosed (Nov 2024)
- Website: definigen.com
- Phone: +4401223497113
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/pixlbio-formerly-definigen-85065 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.